Tuesday, November 10, 2026

GBP/EUR Is 1% Up In The Last 21 Sessions

GBP/EUR Is 1% Up In The Last 21 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.53% for the last 21 sessions. At 08:08 EST on Tuesday, 13 June, GBP/EUR (GBPEUR) is $1.16.

GBP/EUR's yearly highs and lows, it's 7.704% up from its 52-week low and 2.861% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was 0.22%, 0.11%, and 0.24%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.22% (last week), 0.20% (last month), and 0.24% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy edges upward as US bond yields propel gains amid fed-boj’s decisions. According to FXStreet on Monday, 12 June, "However, from a medium-term view, with the daily Exponential Moving Averages (EMAs) positioned below the spot price, the pair is upward, but it needs to crack the top of the range, so the USD/JPY can test the year-to-date (YTD) high of 140.92. ", "The USD/JPY is trading at 139.65, printing modest gains of 0.22% after hitting a daily low of 139.06."
  • Usd/jpy prods yen bears near 139.50 as yields retreat, risk dwindles ahead of US inflation. According to FXStreet on Tuesday, 13 June, "It should be noted that the cautious mood ahead of the US inflation data and the looming $3.0 trillion worth of bond issuance from the US Treasury Department, due to the debt-ceiling deal, also exert downside pressure on the sentiment and the USD/JPY price. ", "The RSI (14) line's retreat joins the increasing strength of the bearish MACD signals to challenge the USD/JPY buyers within a two-week-old symmetrical triangle, currently between 139.90 and 138.85."
  • Boj: A lack of policy change is priced-in and May leave usd/jpy in a range – socgen. According to FXStreet on Monday, 12 June, "That a clear signal from the BoJ hasn't weakened the Yen much at all, suggests that a lack of policy change is priced-in, and may leave USD/JPY in a range, but the options market is right to price for greater downside than upside potential in USD/JPY."
  • Usd/jpy ignores downbeat Japan ppi, boj’s wakatabe to drop toward 139.00, focus on US inflation, fed. According to FXStreet on Monday, 12 June, "A two-week-old symmetrical triangle restricts immediate USD/JPY moves between 140.00 and 138.85.", "Moving on, a light calendar on Monday may restrict intraday moves of the USD/JPY pair. "
  • Usd/jpy strengthens beyond mid-139.00s on modest USD uptick, lacks bullish conviction. According to FXStreet on Monday, 12 June, "The US Dollar (USD), on the other hand, builds on Friday's modest bounce from its lowest level since May 24 and gains some follow-through traction, which is seen as another factor that contributes to the bid tone surrounding the USD/JPY pair. ", "The USD/JPY pair gains some positive traction for the second successive day and climbs back above mid-139.00s during the Asian session on Monday."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com
GBP/EUR Is 1% Up In The Last 21 Sessions | Via News